ArticleJournal of gynecologic oncology2013
Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia.
Article in Journal of gynecologic oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia.The Cochrane database of systematic reviews · 2016Pooled it
- Medical interventions for high-grade vulval intraepithelial neoplasia.The Cochrane database of systematic reviews · 2015Pooled it
- Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial.International journal of cancer · 2026Trial
- Combined HPV 16 E2 and L1 methylation predict response to treatment with cidofovir and imiquimod in patients with vulval intraepithelial neoplasia.Cancer biomarkers : section A of Disease markers · 2022Trial
- HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial.Journal for immunotherapy of cancer · 2021Trial
- Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN).BJOG : an international journal of obstetrics and gynaecology · 2018Trial
- Evaluating the effectiveness of various treatment modalities in vulvar high-grade squamous intraepithelial lesions (vHSIL): a systematic review.Gynecologic oncology reports · 2026Article
- Vulval Intraepithelial Neoplasia: A 15-Year Review of Treatment Outcomes in a UK Centre.Cureus · 2025Article
- COInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region.Oncotarget · 2025Article
- Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination.Nature reviews. Clinical oncology · 2024Review
- Vulval premalignant lesions: a review article.Obstetrics & gynecology science · 2024Article
- Multicentricity and the Risk of Recurrence/Persistence After Laser Vaporization for High-Grade Vulvar and Vaginal Intraepithelial Neoplasia.World journal of oncology · 2024Article
- 5-aminolevulinic acid induced photodynamic reactions in diagnosis and therapy for female lower genital tract diseases.Frontiers in medicine · 2024Review
- The Vulvar Cancer Risk in Differentiated Vulvar Intraepithelial Neoplasia: A Systematic Review.Cancers · 2021Review
- The Major Constituent of Green Tea, Epigallocatechin-3-Gallate (EGCG), Inhibits the Growth of HPV18-Infected Keratinocytes by Stimulating Proteasomal Turnover of the E6 and E7 Oncoproteins.Pathogens (Basel, Switzerland) · 2021Article
- Vulvar intraepithelial neoplasia: Incidence and long-term risk of vulvar squamous cell carcinoma.International journal of cancer · 2021Article
- Modified Turnbull-Cutait anastomosis with fasciocutaneous flap reconstruction for radical excision of vulvar and anal intraepithelial neoplasia.Techniques in coloproctology · 2019Article
- Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol.JAMA network open · 2019Article
- Natural Antibodies to Human Papillomavirus 16 and Recurrence of Vulvar High-Grade Intraepithelial Neoplasia (VIN3).Journal of lower genital tract disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe malignant potential of intraepithelial neoplasia of the vulva and vagina after treatment is not well defined. Our objective was to examine risk factors for recurrence and invasive disease.
methodsFour hundred sixty-four women with biopsy proven high-grade intraepithelial neoplasia of the vulva and vagina were identified in the electronic databases of four colposcopy clinics. Inclusion criteria were a follow-up of more than one year, no history of invasive cancer and no invasive cancer within the first year after initial treatment. We investigated the potential factors associated with recurrence and progression using a logistic regression analysis to estimate odds ratios (ORs) and 95% confidence intervals (CIs).
resultsOf the 411 eligible patients, 123 patients (29.9%) recurred later than one year after initial treatment and 24 patients (5.8%) progressed to invasive disease. According to multivariate analyses, the risk factors associated with recurrence were multifocality (OR, 3.33; 95% CI, 2.02 to 5.51), immunosuppression (OR, 2.51; 95% CI, 1.09 to 5.81), excision as initial treatment (vs. laser evaporation; OR, 1.79; 95% CI, 1.11 to 2.91) and smoking (OR, 1.61; 95% CI, 1.02 to 2.55). Risk factors for progression to invasive disease were immunosuppression (OR, 4.00; 95% CI, 1.30 to 12.25), multifocality (OR, 3.05; 95% CI, 1.25 to 7.43) and smoking (OR, 2.97; 95% CI, 1.16 to 7.60), but not treatment modality.
conclusionLaser evaporation combined with extensive biopsy is at least as efficacious as initial treatment of intraepithelial neoplasia with excision. Smoking is a risk factor for both recurrence and progression to invasive disease. Hence, smoking cessation should be advised and maintaining a long follow-up period due to late relapses is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.